BCAX
Bicara Therapeutics Inc. Common Stock
$23.17
-0.17
(-0.73%)
Mkt Cap
1.52B
Volume
296,876
52W Range
10.295-30.99
Sector
Healthcare
Beta
-0.82
EPS (TTM)
-3.10 USD
P/E Ratio
-6.68
Revenue (TTM)
0 USD
Rev Growth (5Y)
N/A
EPS Growth (5Y)
N/A
Company Description
Bicara Therapeutics Inc., a biopharmaceutical firm in the clinical development phase, is headquartered in Boston, Massachusetts. Established in 2018, the company specializes in creating innovative, dual-action treatments specifically for solid tumors. At the forefront of their pipeline is ficerafusp alfa, a unique antibody designed to tackle solid cancers. This bifunctional therapeutic agent works by simultaneously engaging the epidermal growth factor receptor (EGFR) and binding to human transforming growth factor beta (TGF-b). Bicara Therapeutics operates as a subsidiary of Biocon Limited.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 |
| Net Income | (137.95M) | (68.00M) | (51.98M) | (37.84M) |
| EPS | -2.52 | -1.25 | -1.00 | -0.73 |
| Free Cash Flow | (107.11M) | (74.82M) | (46.21M) | (32.27M) |
| FCF / Share | -1.96 | -1.37 | -0.89 | -0.62 |
| Operating CF | (106.83M) | (74.75M) | (45.63M) | (32.08M) |
| Total Assets | 430.99M | 569.20M | 233.98M | 6.70M |
| Total Debt | 1.71M | 738,000 | 657,000 | 0 |
| Cash & Equiv | 96.69M | 489.71M | 230.44M | 4.16M |
| Book Value | 401.45M | 491.88M | 218.51M | (17.28M) |
| Return on Equity | -0.34 | -0.14 | -0.24 | N/A |
| Metric | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (55.44M) | (56.21M) | (37.39M) | (36.33M) | (27.39M) | (36.85M) | (20.96M) | (17.48M) | (17.05M) | (12.51M) | (12.44M) | (22.84M) |
| EPS | -0.82 | -0.93 | -0.68 | -0.67 | -0.50 | -0.68 | -0.38 | -0.32 | -0.27 | -0.27 | -0.23 | -0.42 |
| Free Cash Flow | (44.27M) | (37.57M) | (24.12M) | (29.29M) | (25.59M) | (28.11M) | (30.07M) | (17.23M) | (12.93M) | (14.59M) | (8.47M) | (10.68M) |
| FCF / Share | -0.65 | -0.62 | -0.44 | -0.54 | -0.47 | -0.52 | -0.55 | -0.32 | -0.24 | -0.27 | -0.16 | -0.20 |
| Operating CF | (44.21M) | (37.51M) | (23.89M) | (29.25M) | (25.59M) | (28.11M) | (30.03M) | (17.22M) | (12.91M) | (14.59M) | (8.04M) | (10.53M) |
| Total Assets | 512.24M | 553.60M | 430.99M | 424.69M | 453.59M | 478.08M | 569.20M | 524.17M | 208.78M | 208.78M | 233.98M | N/A |
| Total Debt | 1.16M | 1.44M | 1.71M | 1.98M | 2.24M | 591,000 | 738,000 | 445,000 | 517,000 | 517,000 | 657,000 | N/A |
| Cash & Equiv | 96.60M | 323.46M | 96.69M | 171.67M | 436.61M | 462.06M | 489.71M | 520.76M | 203.85M | 203.85M | 230.44M | N/A |
| Book Value | 468.77M | 513.96M | 401.45M | 402.78M | 435.20M | 458.96M | 491.88M | 509.56M | (174.78M) | 192.50M | 218.51M | N/A |
| Return on Equity | -0.12 | -0.11 | -0.09 | -0.09 | -0.06 | -0.08 | -0.04 | -0.03 | N/A | -0.06 | -0.06 | N/A |
BCAX News
Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
Dimensional Fund Advisors LP Increases Stock Position in Bicara Therapeutics Inc. $BCAX
Bicara Therapeutics: My Optimism Is Building Despite Recent Market Headwinds
Bicara Therapeutics Analysts Raise Their Forecasts After Q2 Results
Bicara Therapeutics Inc. (BCAX) Q2 2026 Earnings Call Transcript
Bicara Therapeutics Q2 Earnings Call Highlights
Bicara Therapeutics to Report Second Quarter 2026 Financial Results and Business Updates on August 11, 2026, at 8:30 AM ET
Bicara Therapeutics Announces Appointments of Jeremy Bender and Christy Oliger to Board of Directors
Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)